Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBITDA: 2013-2024

Historic EBITDA for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$344.2 million.

  • ImmunityBio's EBITDA rose 30.68% to -$55.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$260.7 million, marking a year-over-year increase of 27.61%. This contributed to the annual value of -$344.2 million for FY2024, which is 4.99% up from last year.
  • Per ImmunityBio's latest filing, its EBITDA stood at -$344.2 million for FY2024, which was up 4.99% from -$362.2 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's EBITDA peaked at -$220.9 million during FY2020, and registered a low of -$362.2 million during FY2023.
  • In the last 3 years, ImmunityBio's EBITDA had a median value of -$351.3 million in 2022 and averaged -$352.6 million.
  • In the last 5 years, ImmunityBio's EBITDA tumbled by 49.53% in 2021 and then grew by 4.99% in 2024.
  • ImmunityBio's EBITDA (Yearly) stood at -$220.9 million in 2020, then tumbled by 49.53% to -$330.3 million in 2021, then declined by 6.36% to -$351.3 million in 2022, then declined by 3.12% to -$362.2 million in 2023, then rose by 4.99% to -$344.2 million in 2024.